navigation navigation
navigation

News

28 Sep 2018

YM&U joins forces with Trilantic Europe following rebrand

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

24 Jul 2018

Gamenet Group signed the agreement for the acquisition of 100% of GoldBet

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

15 Dec 2017

Trilantic Europe invests in the Oberberg Group

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

6 Dec 2017

Gamenet Group completed the listing on Borsa Italiana

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

4 Dec 2017

Elisabetta Franchi purchases 25% of Betty Blue S.p.A. from Trilantic Europe

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

2 Nov 2017

Talgo shortlisted for HS2 rolling stock procurement

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

1 Jun 2017

Trilantic Europe invests in leading bioethanol business in Spain and France

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

7 Apr 2017

Trilantic Europe becomes a shareholder in Pacha Group

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

28 Nov 2016

Talgo wins the most important high-speed tender in Europe with its new Avril, the most advanced high-speed train

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

24 Feb 2016

Trilantic Europe Invests In Maugeri, Leading Italian Non-Acute Private Hospital Operator

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

13 Oct 2015

Trilantic Europe completes acquisition of 90% stake in leading Italian pharmaceuticals producer Doppel Farmaceutici

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

1 Jul 2015

Trilantic Europe raises €900 million

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

1 Jul 2015

IPO of Trilantic Europe IV’s portfolio companies, Talgo and Euskaltel

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

26 Mar 2015

Prettl and Trilantic Europe announce a partnership agreement

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

14 Jan 2015

Trilantic Capital Partners has realised its investment in Clarion Events

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

17 Oct 2013

Trilantic acquires stake in Elisabetta Franchi

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

16 Sep 2013

Gamenet successfully issues €200mn in its debut bond offering

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

26 Jun 2013

Spain's Talgo Awarded €482 million Contract In Kazakhstan

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

20 Nov 2012

Trilantic Europe exits Istanbul Doors Group, owner of the leading restaurants in Istanbul and Tom Aiken’s restaurants in London

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

14 May 2012

Marex Spectron to acquire Schneider Trading Associates Pro-Trader Division

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

12 Dec 2011

Talgo manufacturing facility opens in Kazakhstan

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

26 Oct 2011

Talgo awarded the High-Speed Mecca-Medina mega-contract

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

12 Apr 2011

Michel Léonard joins Trilantic Capital Partners as operating partner

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

24 Mar 2011

The Istanbul Doors Restaurant Group Acquires the Restaurant Business of Michelin-Starred Chef Tom Aikens

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

22 Mar 2011

Marex Group Reaches Agreement to Acquire Spectron Group

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

14 Feb 2011

Appointment of John Danilovich to Trilantic European Advisory Council

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

17 Jan 2011

Refresco Group Announces its Intention to Acquire Spumador

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

14 Jan 2011

Trilantic Capital Partners commits up to €50 million in LeYa

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

7 Jan 2011

Trilantic Capital Partners to Invest €53 million in Gamenet

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

11 Nov 2010

Talgo is awarded the contract to renew and expand the intercity passenger train coaches of the national railway company of Kazakhstan

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

28 Jul 2010

Thai Union Frozen Products Board of Directors Approves Acquisition of MW Brands from Trilantic Capital Partners

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

10 Feb 2010

Trilantic Capital Partners has Successfully Realized its Ownership Stake in Industria de Turbo Propulsores S.A.

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

24 Sep 2009

Talgo: Spanish Minister of Transportation to Support Talgo in its Internationalization

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

17 Jul 2009

Talgo: Governor Doyle Announces Agreement with Talgo to Bring New Trains, Assembly and Maintenance Facilities to Wisconsin

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

16 Jul 2009

Istanbul Doors: Company Receives a Special Award at the Retailer Awards Recently Held in Istanbul

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

9 Apr 2009

Istanbul Doors: Group Launches New Italian Restaurant Concepts

Trilantic Europe ('Trilantic Europe'), a private equity firm focused on mid-market transactions in Europe, announces today that it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici ('Doppel' or the 'Company'), after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a Contract Development and Manufacturing Organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding. Following the completion of the transaction, Paolo Lanfranchi has moved from his previous role as Managing Director to become Chairman of Doppel. Giuseppe Cassisi, who has 30 years' experience in the pharmaceuticals and CDMO sector, has become the Company's CEO.

Trilantic Europe and Doppel's management team have put in place a strategy focused on expanding Doppel both organically and as a platform to acquire other players in the CDMO sector. The strategy also includes plans to increase Doppel's presence in international markets, such as the United States and the Far East, strengthening the Company's offer in research and development, strategic growth through the acquisition of niche capabilities such as injectable biotechnology medicines, and the development of greenfield projects.

Doppel, which was founded in 1994, has contracts with blue-chip Italian and international clients. The company has 460 employees and operates from two production plants in northern Italy, Cortemaggiore and Rozzano. The Company principally manufactures and packs pharmaceutical products such as pills, pharmaceutical granules, creams, tablets, oral solutions, sprays and injection vials, produced under asepsis conditions or with terminal sterilisation. In 2009, the company launched a nutrition division at the Cortemaggiore plant, dedicated to the contract manufacturing and packaging of effervescent granules.

Since 2003, Doppel has also been active in food, nutraceutical and cosmetic supplements as well as medical devices thanks to its 24.7% shareholding in Procemsa Farmaceutici.

In 2014, Doppel had net revenue of €83.4 million and EBITDA of €12.3 million. The Italian market accounted for 63% of Doppel's turnover with the remaining 37% coming from international markets.

Trilantic Europe was advised on legal matters by Studio Legale Associato La Torre Morgese Cèsaro Rio, while Ethica Corporate Finance acted as financial adviser on the transaction. The selling shareholders were advised on legal matters by Studio Legale Associato d'Urso Gatti Pavesi Bianchi.

Enquiries:

Trilantic Europe
Grant Ringshaw/ Agnès Riousse

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in Western Europe. Trilantic Europe employs flexible transaction structures and has a strong heritage of partnering with family-owned businesses as well as providing growth capital to outstanding management teams. Trilantic Europe is differentiated from our competition by the firm's history of disciplined, successful investing, the demonstrated capability to supply flexible and growth capital and to be true partners with the management of our portfolio companies. The firm often applies a 'buy in' not 'buy out' approach and is determined to deliver value both to the Limited Partners and the management teams that it supports. Trilantic Europe's primary investment focus is in the consumer & leisure, industrials, TMT, pharmaceutical/ medical, business services and healthcare sectors. Trilantic currently manages two institutional private equity funds with total assets of around €1.5 billion.

Contact

Trilantic Europe

London

35 Portman Square, London W1H 6LR, United Kingdom

Guernsey

Le Marchant Street, St Peter Port, Guernsey GY1 4HY

Luxembourg

26 Bd Royal, L-2449 Luxembourg, Luxembourg